Published in Cancer Weekly, August 8th, 2006
According to a study from Germany, "Drug-targeting strategies can increase the efficacy and reduce the side effects and toxicity of conventional chemotherapy or may lead to new radiolabeled molecules useful for diagnosis and therapy. To identify and characterize new carrier molecules, we evaluated a peptide that had been identified by phage display technology. The peptide p160 was prepared by solid-phase peptide synthesis and radiolabeled with I-125 or I-131."
"The radiolabeled peptide and derivatives of it were used to study binding and internalization in vitro and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.